Trizivir ARV treatment results in Republic of Moldova
Introduction: Assessing efficiency of Trizivir in the ARV treatment of HIV patients.
Methods: Trizivir treated HIV patients’ medical files analysis.
Results: Trizivir is the first tri-component antiretroviral drug used in Republic of Moldova. It was implemented as a first-line option for several reasons: a very simple scheme of administration as 1 tab.×2/day; a relatively low cost for that period (June 2003) as 1600 USD/year; possibility to be used in opportunistic infections as TBC too. During the first year 51 patients have started the treatment with Trizivir. At the beginning of 2005 Trizivir treatment was continuing in 33 cases. Since 2003 18 patients abandoned the course. The first evolutional analysis of 33 patients continuing Trizivir treatment was done after 48 weeks from the beginning. Some adverse reactions were revealed: in 12 (36,4%) cases – fever > 38ºC during 3-4 days; in 18 (54,5%) cases – nausea; in 15 (45,5%) cases – vomiting. Other reactions also occurred: diarrhea – in 5 (15%) cases, rash syndrome for 1-2 weeks – in 3 (9%), immune recovery syndrome – in 8 (24,3%) cases. The CD4+ level gained a 2-fold average increase from 331 to 709 cells/mm³. Only in 4 cases RNA HIV load was determined at the ARV treatment beginning. After 48 weeks the RNA HIV load overall state was < 400 copies/ml in 28 (88%) cases.
Conclusions: 1. Trizivir treatment is well-accepted and well-tolerated by patients and reveals a high compliance. 2. Immunological and virusological data confirm the efficiency of Trizivir treatment after 48 weeks. 3. No anaphylactic reactions were registered under Trizivir treatment. 4. The recent reports insinuate a possible combination of Trizivir with EFV for obtaining a durable response in case of an undetectable level of RNA HIV load.
Climasevschi I.1, Luca L.1, Popovici S.1, Betiu M.1
1Republican Dermatovenerologic Dispensary, Infectious Diseases Department, Chisinau, Republic of Moldava